| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/14/2005 | US20050153930 Via gadolinium compounds as calcium channel blockers; drug screening |
| 07/14/2005 | US20050153920 Ribozymes used as prodrugs |
| 07/14/2005 | US20050153912 Antiviral oligonucleotides targeting viral families |
| 07/14/2005 | US20050153904 Dialysis method |
| 07/14/2005 | US20050153892 Compound B as an angiogenic agent in combination with human growth factors |
| 07/14/2005 | US20050153891 proteins coded by murine herpes viruses, or homologues, use in binding chemokines, to produce an immunomodulatory or antiinflammatory effects |
| 07/14/2005 | US20050153888 oligopeptides capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM), used for treatment of normal, degenerated and damaged NCAM presenting cells |
| 07/14/2005 | US20050153878 Fgfr agonists |
| 07/14/2005 | US20050153871 Administering N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016) to increase or prevent a decrease in cerebral blood flow |
| 07/14/2005 | US20050153372 Using calmodulin-dependent protein kinase and/or calcineurin as tool in detecting modulators of nervous system and brain disorders; enzyme inhibitors |
| 07/14/2005 | US20050153332 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 07/14/2005 | US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders |
| 07/14/2005 | US20050152999 supercritically extracting an herb to obtain an oil extract and a residue;extracting the residue in a water/alcohol liquid mixture to obtain a post-supercritical hydroalcoholic extract; evaporating the water/alcohol liquid to form a powdered extract; mixing the powdered extract with the oil extract. |
| 07/14/2005 | US20050152995 comprising contacting tissues with agents that prevents glial scar formation and optionally agent that increases bcl-2 protein levels in neurons |
| 07/14/2005 | US20050152991 peroxyoctanoic acid, octanoic acid, carrier, and solubilizer, oxidizers; can be readily made, and/or can exhibit reduced odor; microbiocide |
| 07/14/2005 | US20050152989 Method for treating irritable bowel syndrome |
| 07/14/2005 | US20050152978 Capsule, tablet with enteric, protective coatings; bioavailability |
| 07/14/2005 | US20050152930 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/14/2005 | US20050152925 Method for treating pain by peripheral administration of a neurotoxin |
| 07/14/2005 | US20050152891 for delivery and controlled release to treatment sites, such as in the area of an implanted stents |
| 07/14/2005 | US20050152884 strains of lactic acid bacteria obtained by isolation from mammallian gastrointestinal systems having probiotic activity in animals; animal feeds |
| 07/14/2005 | US20050152881 Composition of matrix suitable for implantation in humans defatting shredded allogenic human muscle tissues |
| 07/14/2005 | US20050152880 Matrix composition for human grafts/implants |
| 07/14/2005 | US20050152874 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells |
| 07/14/2005 | US20050152871 treating the subject in need with one or more chemokines and/or a DNA damaging agent inducing said chemokine(s); |
| 07/14/2005 | US20050152856 0.5-7% by weight of D,L- alpha -lipoic acid, 0.05-0.5% by weight of coenzyme Q-10 and 0.01-3% by weight of acetyl-L-carnitine hydrochloride; treatment of visible sun injuries caused by processes involving the action of free radicals |
| 07/14/2005 | US20050152852 cocoa inhibits the growth of the periodontal disease bacteria such as Porphyromonas gingivalis and has excellent antibacterial activity against periodontal disease bacteria |
| 07/14/2005 | US20050152847 Novel formulation |
| 07/14/2005 | US20050152846 Hydrofluoroalkane (HFA) propellant and co-solvents; inhalants; storage stability; deep lung penetration |
| 07/14/2005 | DE10131145B4 Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen Composition for cell-specific transfer of drugs |
| 07/14/2005 | CA2551657A1 Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2551637A1 Melatonin combination therapy for improving sleep quality |
| 07/14/2005 | CA2551602A1 Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| 07/14/2005 | CA2551580A1 Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2551100A1 Compositions and methods for combined therapy of disease |
| 07/14/2005 | CA2550679A1 Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders |
| 07/14/2005 | CA2550342A1 Effervescent preparation of a basic medicinal substance |
| 07/14/2005 | CA2550309A1 Canine probiotic bifidobacteria pseudolongum |
| 07/14/2005 | CA2550307A1 Canine probiotic bifidobacteria globosum |
| 07/14/2005 | CA2549638A1 Therapeutic combination for cognition enhancement and psychotic disorders |
| 07/14/2005 | CA2548357A1 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2548313A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| 07/14/2005 | CA2548305A1 Use of alginate matrices to control cell growth |
| 07/14/2005 | CA2547852A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 07/14/2005 | CA2507343A1 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents |
| 07/13/2005 | EP1552850A2 A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| 07/13/2005 | EP1552849A1 Immunotherapeutic for cancer |
| 07/13/2005 | EP1552846A2 Use of heparinases to decrease inflammatory responses |
| 07/13/2005 | EP1552841A1 Arsenic sulfide compounds and derivates thereof for the treatment of malignancies |
| 07/13/2005 | EP1552839A1 Separate type medical material |
| 07/13/2005 | EP1552825A1 Therapeutic agent for overactive bladder |
| 07/13/2005 | EP1552745A1 Therapeutic combinations of venous dilators and arterial dilators |
| 07/13/2005 | EP1552462A1 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 07/13/2005 | EP1551990A2 Diagnosis and treatment of chemoresistant tumors |
| 07/13/2005 | EP1551964A2 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 07/13/2005 | EP1551962A2 Mitotic kinesin binding site |
| 07/13/2005 | EP1551955A2 Methods of implanting mesenchymal stem cells for tissue repair and formation |
| 07/13/2005 | EP1551872A2 G-protein coupled receptors |
| 07/13/2005 | EP1551857A2 A robust, inducible cardiac preferred expression system for transgenesis |
| 07/13/2005 | EP1551812A2 Mitotic kinesin inhibitors |
| 07/13/2005 | EP1551794A1 Ureido-substituted aniline compounds useful as serine protease inhibitors |
| 07/13/2005 | EP1551790A2 Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 07/13/2005 | EP1551495A2 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
| 07/13/2005 | EP1551452A1 Compositions and methods for therapeutic treatment |
| 07/13/2005 | EP1551440A2 Uses of human zven proteins and polynucleotides |
| 07/13/2005 | EP1551436A2 Formulations for amylin agonist peptides |
| 07/13/2005 | EP1551426A2 Methods of administering fgf18 |
| 07/13/2005 | EP1551421A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/13/2005 | EP1551419A2 Relief of aids symptoms |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551413A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 07/13/2005 | EP1551411A2 Synergistic methods and compositions for treating cancer |
| 07/13/2005 | EP1551407A1 Treatment of aml |
| 07/13/2005 | EP1551395A1 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist |
| 07/13/2005 | EP1551394A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 07/13/2005 | EP1551393A2 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| 07/13/2005 | EP1551387A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 07/13/2005 | EP1551382A2 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 07/13/2005 | EP1551380A1 A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
| 07/13/2005 | EP1551378A2 Epo d + 5-fu/gemcitabine |
| 07/13/2005 | EP1551376A2 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 07/13/2005 | EP1551221A2 Nucleic acid compositions for stimulating immune responses |
| 07/13/2005 | EP1432379A4 Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| 07/13/2005 | EP1414479A4 Peptide for regulation of tissue plasminogen activator |
| 07/13/2005 | EP1266039B1 Method and kit for the screening, the detection and/or the quantification of transcriptional factors |
| 07/13/2005 | EP1248636B1 Dextrin containing compositions for prevention of adhesions |
| 07/13/2005 | EP1202722B1 Uses of compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP0750512B1 A medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction |
| 07/13/2005 | CN1639343A Method for detection of leptin receptor ligands |
| 07/13/2005 | CN1639324A Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 07/13/2005 | CN1639323A Vesicles derived from T cells, production and uses |
| 07/13/2005 | CN1639191A 鼠李糖结合蛋白 Rhamnose-binding protein |
| 07/13/2005 | CN1639187A Macrocyclic peptides active against the hepatitis C virus |
| 07/13/2005 | CN1639185A Cancer-associated epitope |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639158A Thiazole derivatives as NPY receptor antagonists |
| 07/13/2005 | CN1639140A Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |